Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Luminal ammonia and ammonia absorption processes in the colon represent a critical physiological pathway for nitrogen excretion and a primary therapeutic target in the management of hepatic encephalopathy. Ammonia is generated in the colonic lumen through the action of bacterial ureases on urea and the deamination of nitrogenous compounds by enteric microbiota (PubMed: 23639605). Under normal conditions, ammonia exists in equilibrium between gaseous NH3 and ionic NH4+; NH3 readily diffuses across the colonic epithelium into the portal circulation, while NH4+ transport is mediated by specific proteins such as Rh glycoproteins (RhBG, RhCG) and potassium transporters (PubMed: 15591005). In patients with liver failure, the liver's inability to detoxify portal ammonia via the urea cycle leads to systemic hyperammonemia and neurotoxicity. Pharmacological interventions like lactulose lower luminal pH to favor the formation of non-absorbable NH4+, a mechanism known as ammonia trapping (PubMed: 25012631). Additionally, non-absorbable antibiotics like rifaximin reduce the burden of ammonia-producing bacteria to decrease the total luminal ammonia load (PubMed: 20335583). Targeting these processes is essential for reducing the neuropsychiatric complications associated with chronic liver disease and urea cycle disorders. This target encompasses both the chemical state of the metabolite and the biological machinery, including both bacterial enzymes and human transporters, that facilitates its movement into the bloodstream.
The primary mechanisms of action for drugs targeting these processes include the acidification of the colonic lumen to trap ammonia as non-absorbable ammonium ions (NH4+), the reduction of ammonia-producing enteric bacteria through targeted antimicrobial action, and the promotion of osmotic catharsis to reduce the residence time of nitrogenous waste in the gut.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Luminal ammonia and ammonia absorption processes in the colon.